


PHARMACEUTICAL 2018



BIOSPECIFICS TECHNOLOGIES CORP Rank 4 of 342





PHARMACEUTICAL 2018



BIOSPECIFICS TECHNOLOGIES CORP Rank 4 of 342

The relative strengths and weaknesses of BIOSPECIFICS TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOSPECIFICS TECHNOLOGIES CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 100% points. The greatest weakness of BIOSPECIFICS TECHNOLOGIES CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 6.0% points.

The company's Economic Capital Ratio, given in the ranking table, is 354%, being 309% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	66,381
Cost of Goods Sold	0
Intangible Assets	398
Liabilities, Current	2,139
Liabilities, Non-Current	0
Other Assets	8,218
Other Compr. Net Income	0
Other Expenses	7,038
Other Liabilities	0
Other Net Income	688
Other Revenues	27,444
Property and Equipment	0
Research and Development	1,223
Selling, General and Administrative Expense	8,542

Output Variable	Value in 1000 USD
Assets	74,996
Liabilities	2,139
Expenses	16,803
Revenues	27,444
Stockholders Equity	72,858
Net Income	11,328
Comprehensive Net Income	11,328
Economic Capital Ratio	354%

